Search

Your search keyword '"Nakamura, Ryotaro"' showing total 306 results

Search Constraints

Start Over You searched for: Author "Nakamura, Ryotaro" Remove constraint Author: "Nakamura, Ryotaro" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
306 results on '"Nakamura, Ryotaro"'

Search Results

2. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

3. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

4. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

5. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

6. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

7. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

9. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

10. A Day 14 Endpoint for Acute GVHD Clinical Trials

11. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

13. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

14. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

15. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

16. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

17. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

18. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

19. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

20. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

22. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

23. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

25. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

26. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

27. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

31. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

32. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.

33. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

34. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.

35. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

36. Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis.

37. Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens.

38. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

39. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

41. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

42. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

43. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

44. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

45. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

46. Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.

47. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.

48. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS

50. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

Catalog

Books, media, physical & digital resources